Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Mashup Score: 2

news.bms.com

Study met primary and key secondary endpoints, demonstrating a highly statistically significant improvement in event-free survival, complete response rate and progression-free survival compared to standard of care Breyanzi safety results consistent with data from pivotal TRANSCEND NHL 001 trial Results represent the first time a therapy has demonstrated benefit compared to high-dose chemotherapy...

  • Axi-cel met primary endpoint in phase III trial of DLBCL in first relapse vs salvage chemo and Auto. at median f/u of 2 years EFS; hazard ratio 0.398, p <0.0001. No OS benefit yet, but not yet mature.